Pricing Log in Create free account
Sunday 18 October 2026 Export SEER’s income statement to Excel — free account

Seer, Inc.

SEER Healthcare Biotechnology

Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.03 0.01 −0.49%
Market cap
$113.0M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.55
Beneish M
−2.98
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.19
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 — — 2 — — 1 — 1 1 — —
Insider Ownership 33.14%

Capital & Financial Ratios $m

Market Cap 112.96
Revenue 14.22
Net Income (67.96)
Free Cash Flow (43.98)
Net Debt (152.85)
Current Ratio 14.74 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.71) (negative: loss-making)
P/S ratio 7.88
P/B ratio 0.50
Past 5Y EPS Growth —
This Y EPS Growth 14.06%
Next Y EPS Growth 4.09%
Next Y revenue growth (2.88%) (below 0%: weak)
Next 5Y EPS Growth 12.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.9×, against a ten-year median of −4.8×; over the ten years it ranged from −13.6× in 2023 to 4,656× in 2021.
P/S against its own 10 years 34.89%
10-year low 10-year high
P/B against its own 10 years 52.58%
10-year low 10-year high
EV/FCF against its own 10 years 11.23%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 316 236 186 153
Receivables 7 6 6 3
Inventory 4 7 8 8
Other — — — —
331 253 202 166
2023 2024 2025 Q'26
Payables 1 5 6 3
ST’ Debt — — — —
Other 0 0 0 0
13 15 16 11

Compound Annual Growth %

10y 5y 3y
Sales — 90.78% 2.28%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (9.69%) (16.60%)

Revenue $m

Mar Jun Sep Dec Year
’26 3 3 — — —
’25 4 4 4 4 17
’24 3 3 4 4 14
’23 4 4 4 4 17
’22 3 4 4 5 15
’21 0 1 2 3 7
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (10) — — —
’25 (11) (15) (8) (11) (44)
’24 (10) (10) (14) (11) (46)
’23 (19) (15) (14) (10) (59)
’22 (19) (14) (13) (14) (61)
’21 (15) (10) (9) (12) (46)
’20 (5) (5) (5) (5) (21)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (10) — — —
’25 (12) (15) (8) (11) (46)
’24 (11) (11) (16) (11) (49)
’23 (19) (16) (19) (12) (66)
’22 (20) (16) (16) (19) (71)
’21 (16) (12) (11) (14) (53)
’20 (6) (7) (6) (6) (25)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.30) (0.31) — — —
’25 (0.34) (0.33) (0.32) (0.29) (1.28)
’24 (0.32) (0.35) (0.35) (0.37) (1.39)
’23 (0.38) (0.37) (0.33) (0.28) (1.35)
’22 (0.38) (0.37) (0.38) (0.36) (1.49)
’21 (0.27) (0.27) (0.30) (0.32) (1.17)
’20 (0.61) (0.63) (0.80) (0.54) (2.48)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 44.00 19.92 4.86 1.46 1.51 1.62

Analyst estimates 2026–2028

Powerpack
High — — — — 86.13 86.55 23.75 6.18 2.63 2.50
People
People Employees — — — — 60 118 164 147 134 124
Revenue/emp, $m — — — 0.00 0.01 0.06 0.09 0.11 0.11 0.13
Income, $m
Income, $m Revenue — — — 0 1 7 15 17 14 17
Gross margin, % — — 0.00 100.00 100.00 51.56 45.78 51.05 49.79 51.06
EBT — — (6) (16) (33) (71) (93) (86) (87) (73)
EBT margin, % — — 0.00 (13,825.86) (4,996.19) (1,075.55) (600.05) (517.84) (610.45) (442.75)
Net income — 0 (6) (16) (33) (71) (93) (86) (87) (74)
Depreciation — — 0 0 2 4 3 (6) 9 7
Per share, $
Per share, $ Revenue — — 0.00 0.02 0.05 0.11 0.25 0.26 0.23 0.29
Earnings — — (0.10) (2.31) (2.48) (1.17) (1.49) (1.35) (1.39) (1.28)
Cash flow — — (0.08) (1.88) (1.58) (0.76) (0.97) (0.93) (0.74) (0.77)
Capex — — 0.00 (0.59) (0.34) (0.11) (0.16) (0.11) (0.05) (0.02)
Free cash flow — — (0.08) (2.47) (1.92) (0.88) (1.14) (1.04) (0.79) (0.79)
Book value — — 0.49 12.61 32.66 8.26 7.16 6.22 5.25 4.51
Shares, m — — 61 7 13 61 62 64 62 57
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 1,536.28 2,044.75 209.81 23.57 7.43 10.16 6.34
P/B — — — 0.00 3.11 2.76 0.82 0.31 0.44 0.41
EV/Sales — — — 1,308.71 1,386.42 149.35 (3.61) (11.55) (6.52) (4.87)
EV/FCF — — — (13.39) (35.86) (18.55) 0.79 2.90 1.87 1.77
Cash, $m
Cash, $m Operating cash flow — — (5) (13) (21) (46) (61) (59) (46) (44)
Capex — — 0 (4) (5) (7) (10) (7) (3) (1)
Free cash flow — — (5) (17) (25) (53) (71) (66) (49) (46)
Balance, $m
Balance, $m Working capital — — 28 83 425 398 422 317 238 186
Total debt — — — — — 23 30 — — —
Net debt — — (31) (86) (432) (400) (421) (316) (236) (186)
Shareholders’ equity — — 30 88 432 503 447 397 328 259
Returns, %
Returns, % ROA — — (37.43) (25.27) (12.24) (14.50) (18.10) (18.67) (21.57) (22.21)
ROIC — — 0.00 (636.04) 0.00 (43.44) (235.97) (80.15) (68.63) (66.40)
ROE — — 48.31 122.84 (15.94) (15.23) (19.57) (20.45) (23.91) (25.08)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Seer, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HURA TuHURA Biosciences, Inc. $116.6M — (loss-making) — — n/m −70.46% (below 0%: shrinking) 0.00% 0.00% Compare
NERV Minerva Neurosciences, Inc $115.6M — (loss-making) — (loss-making) — n/m −553.48% (below 0%: shrinking) 0.00% 0.00% Compare
ARMP Armata Pharmaceuticals, Inc. $114.9M — (loss-making) — (loss-making) +15.72% (above 0%: growing) n/m −17.98% (below 0%: shrinking) 100.00% (410.84%) Compare
ENGN enGene Therapeutics Inc $114.6M — (loss-making) — — n/m +28.07% (above 0%: growing) — 0.00% Compare
SEER Seer, Inc. $113.0M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%)
FHTX Foghorn Therapeutics Inc. $112.2M — (loss-making) — (loss-making) +112.68% (above 0%: growing) n/m +14.88% (above 0%: growing) 100.00% (54.78%) Compare
GNLX Genelux Corporation $112.2M — (loss-making) — (loss-making) — n/m −11.18% (below 0%: shrinking) 100.00% 0.00% Compare
LENZ LENZ Therapeutics, Inc. $112.2M — (loss-making) — (loss-making) +9.72% (above 0%: growing) n/m −229.66% (below 0%: shrinking) 94.90% (622.89%) Compare
TNXP Tonix Pharmaceuticals Holding Corp. $110.1M — (loss-making) — (loss-making) +577.88% (above 0%: growing) n/m −178.84% (below 0%: shrinking) 94.81% (314.05%) Compare
Median of peers $113.4M — — +64.20% — −44.22% 94.90% (27.39%)

All 614 Biotechnology stocks →

Seer, Inc. (SEER) key facts

  • Concern: Seer, Inc. reported a net loss of $73.6 million, or a loss of $1.28 per share, for fiscal 2025.
  • Strength: Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024.
  • Seer, Inc. (SEER) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SEER traded at $2.03, a market capitalization of $113.0 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7.9× sales.
  • Return on equity was −25.1% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.55 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Seer, Inc. (SEER) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SEER · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com